Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled trial of BI 685509 in non-diabetic kidney disease
jRCT2031210137Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of avenciguat in chronic kidney disease (CKD) and proteinuric kidney disease (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in log-transformed UACR at 20 weeks. Started Jun 2021; status: recruiting.
02
Drugs
avenciguat
03
Conditions
chronic kidney disease (CKD)proteinuric kidney disease
Beyond the preview
Go deeper on jRCT2031210137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210137.